259
Participants
Start Date
April 30, 2012
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
Placebo
Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
RO5490258
15 mg/kg iv, Day 1 of each 21-day cycle
bevacizumab [Avastin]
15 mg/kg iv, Day 1 of each 21-day cycle
cisplatin/carboplatin
standard dose iv, Day 1 of each 21-day cycle, 4 cycles
paclitaxel
200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
pemetrexed
500 mg/m2, Day 1 of each 21-day cycle
Taipei
Tainan City
Kaohsiung City
Quezon City
Quezon City
Pasig
Daugavpils
Cebu City
Davao City
New York
Orbassano
George Town
Tanjung Bungah
Pulau Pinang
Afula
Milan
Aguascalientes
Cremona
Madrid
Madrid
Hickory
Lawrenceville
Marietta
Chihuahua City
Pamplona
Orlando
Hollywood
Udine
Boynton Beach
Immenhausen
Rennes
Huntsville
Göttingen
León
Grenoble
Taichung
Columbus
Cleveland
Middletown
Indianapolis
Fort Wayne
Fort Wayne
Muncie
Münster
Zaragoza
Minneapolis
Kuala Lumpur
Holon
Harvey
Metairie
Negeri Sembilan
Paris
Paris
Ashkelon
München
Avellino
Scottsdale
Las Vegas
Los Angeles
Northridge
Fullerton
Santa Barbara
Bakersfield
San Luis Obispo
Portland
Bend
Seattle
Ẕerifin
Tel Aviv
Los Angeles
Stanford
Grand Junction
Buenos Aires
La Rioja
Santa Rosa
Halle
Rome
Liepāja
Riga
Riga
Barcelona
Taipei
Aberdeen
Birmingham
Bournemouth
Leeds
Manchester
Lead Sponsor
Genentech, Inc.
INDUSTRY